Press releases
- Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease
- Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- Sage Therapeutics to Participate in Upcoming May Investor Conferences
- Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
- Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
- Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
More ▼
Key statistics
On Friday, SAGE Therapeutics Inc (SG7:DEU) closed at 9.76, 6.62% above its 52-week low of 9.16, set on Jun 11, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.71 |
---|---|
High | 10.03 |
Low | 9.71 |
Bid | 9.84 |
Offer | 10.04 |
Previous close | 9.81 |
Average volume | 133.60 |
---|---|
Shares outstanding | 60.18m |
Free float | 53.00m |
P/E (TTM) | -- |
Market cap | 648.76m USD |
EPS (TTM) | -8.40 USD |
Data delayed at least 15 minutes, as of Jul 05 2024.
More ▼